Fig. S6.

Pharmacodynamic effects of chimeric activator variants on reticulocytes, hematocrit, and total platelets in huGYPA transgenic and nontransgenic mice. This experiment is a repeat of that in Fig. 4, except that proteins were made from stable cell lines, not transient transfections. (A) Transgenic mice received a single i.p. injection of darbepoetin, 10F7-EPO variant, or saline at the indicated concentrations (1 pmol darbepoetin = 37 ng; 1 pmol 10F7-EPO variant = 72 ng). Blood samples were removed by tail-nick on days 0, 4, 7, and 11 postdosing. Measured hematologic parameters were reticulocyte fraction by flow cytometry (B–F) and hematocrit (G–K) and total platelet counts (L–P) by hematology analyzer. Measurements were background-subtracted relative to day 0. Graphs display mean ± SEM (n = 3).